C12N5/0686

PROCESS FOR KIDNEY CELL MANUFACTURE AND TREATMENT

Embodiments described herein relate to a method for preparing cultured cells, the method comprising: obtaining kidney tissue from a human subject; mechanically dissociating the tissue; subjecting the tissue to enzymatic digestion; incubating the tissue with media in a cell culture plate to form cultured cells.

PRODUCTION CELL AND PACKAGING CELL FOR RETROVIRAL VECTOR AND PREPARATION METHOD THEREFOR
20230051793 · 2023-02-16 ·

The present disclosure relates to a method for constructing a producer cell and the producer cell obtained by the method, wherein the producer cell is for producing a retroviral vector carrying a nucleic acid fragment of interest.

PERIPHERAL BLOOD DERIVED SMALL PLURIPOTENT CELLS
20230235288 · 2023-07-27 ·

The present disclosure relates to populations of small pluripotent stem cells derived from peripheral blood, such as human peripheral blood. In some aspects, these small pluripotent stem cells are smaller than known stem cells and express a range of embryonic, hematopoietic, or mesenchymal stem cell markers. Also disclosed herein are methods of isolation and cryopreservation of these populations of small pluripotent stem cells. These small pluripotent stem cells may be differentiated in a wide range of cell types, which can be used in various applications such as the study of cell activity or for treatment of diseases and personalized medicine.

NY-ESO-1-CONTAINING ARTIFICIAL ADJUVANT VECTOR CELL FOR USE IN TREATMENT OF CANCER

An object of the present invention is to provide clinically applicable aAVC-NY-ESO-1 cells stably expressing NY-ESO-1 in order to use aAVC-NY-ESO-1 cells in treating patients having a NY-ESO-1-expressing cancer. The present invention provides, for example, a human-derived cell comprising a polynucleotide encoding CD1d and a polynucleotide encoding NY-ESO-1 or a fragment thereof, wherein the polynucleotide encoding NY-ESO-1 or a fragment thereof is operably linked to an inducible promoter.

Kidney production method

The present invention provides a kidney production method including a step of tissue-specifically removing a metanephric mesenchyme of a metanephros of a non-human animal; a step of transplanting, into the metanephros, a kidney precursor cell derived from a non-human animal which is allogeneic or xenogeneic to the non-human animal; and a step of advancing development of the metanephros, which is a step in which the transplanted kidney precursor cell is differentiated and matured to form a part of the kidney.

METHODS FOR IMPROVED DELIVERY OF THERAPEUTIC AGENTS

The present disclosure provides expression constructs designed to provide for expression of therapeutic proteins from engineered cells. The engineered cells may be encapsulated into implantable elements that allow for the therapeutic protein to be released into from the capsule while protecting the cell from the immune system of a patient into which the capsule is implanted.

PRODUCTION OF EXOSOMES AND USES THEREOF

A method for producing exosomes in a large-scale by using a cyclic tensile bioreactor to stimulate cells to release exosomes. In addition, the exosome having an anti-HLA-G protein specific for cancer is used as a delivery vehicle to deliver therapeutic agents for treating cancer.

GENERATION OF KIDNEY GLOMERULAR SPECIFIC ENDOTHELIAL CELLS AND METHODS OF USE

The present disclosure is directed to method of generating human glomeruli endothelial cells (HGECs) from human endothelial cells (ECs), comprising expressing in human ECs an exogenous nucleic acid encoding a T-box transcription factor 3 (Tbx3), alone or in combination with one or more of PR domain zinc finger protein 1 (Prdm1), GATA Binding Protein 5 (Gata5) and Pre-B-Cell Leukemia Transcription Factor 1 (Pbx1). Disclosed also are HGECs produced by the methods of the instant disclosure, as well as methods for using the same.

NOVEL VERO CELL LINE THAT CAN BE SUSPENSION-CULTURED IN SERUM-FREE MEDIUM, PREPARATION METHOD THEREFOR, AND METHOD FOR PREPARING VIRUSES FOR VACCINES BY USING NOVEL CELL LINE

The present disclosure relates to sVERO 7C2, which is a Vero cell line derived from Vero cells (African Green Monkey Kidney Cell Line) distributed from the WHO and capable of suspension culture without serum components. Further, the present disclosure relates to a culture method for growing the Vero cells and a method for producing a vaccine virus using the Vero cells.

FIBROBLAST HAVING ENHANCED ERYTHROPOIETIN PRODUCTION ABILITY
20220411761 · 2022-12-29 ·

It was found that, by culturing human fibroblasts using a medium supplemented with TNF-α and IL-4, EPO productivity in the fibroblasts can be improved. As a result, fibroblasts having enhanced EPO productivity were found, and means for improving a state where EPO productivity is decreased, and means for treating renal disorder or renal anemia, using the cells were discovered.